A nurse examines a patient in the Emergency Department of Cincinnati Children’s, where researchers successfully tested artificial intelligence-based technology to improve patient recruitment for clinical trials. Researchers report test results in the journal JMIR Medical Informatics.

Credit: Cincinnati Children's

Artificial selection

Improving clinical trial recruitment with AI

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of these studies.

Researchers at Cincinnati Children’s Hospital Medical Center designed and tested a new computerized solution that used artificial intelligence (AI) to effectively identify eligible subjects from Electronic Health Records (EHRs), allowing busy clinical staff to focus their limited time on evaluating the highest quality candidates. The study is published online in JMIR Medical Informatics. It shows that compared to manually screening EHRs to identify study candidates, the system—called the Automated Clinical Trial Eligibility Screener (ACTES)—reduced patient screening time by 34 percent and improved patient enrollment by 11.1 percent. The system also improved the number of patients screened by 14.7 percent and those approached by 11.1 percent.

Because of the large volume of data documented in EHRs, the recruiting processes used now to find relevant information are very labor intensive within the short time frame needed

Yizhao Ni

Busy emergency departments often serve as excellent locations for clinical trial coordinators to find people who may be good study candidates. According to the study’s lead investigator, Yizhao Ni, PhD, Division of Biomedical Informatics, ACTES is designed to streamline what often proves to be inefficient clinical trial recruiting process that doesn’t always catch enough qualified candidates.

“Because of the large volume of data documented in EHRs, the recruiting processes used now to find relevant information are very labor intensive within the short time frame needed,” said Ni. “By leveraging natural language processing and machine learning technologies, ACTES was able to quickly analyze different types of data and automatically determine patients’ suitability for clinical trials.”

The system has natural language processing, which allows computers to understand and interpret human language as the system analyzes large amounts of linguistic data. Machine learning allows computerized systems to automatically learn and evolve from experience without specifically being programmed. This makes it possible for computer programs to process data, extract information, and generate knowledge independently.

Recommended article

Photo

A look into the crystal ball

Experts debate predictive potential of AI

‘Hello, John? You are about to suffer a heart attack – please come to the hospital immediately!’ Will we, one day, be collected by emergency doctors even before we’re ill? If it was up to some AI experts at Medica, this could be the case – soon. Some obstacles must yet be overcome to achieve perfect AI predictions. Yet, during Medica, some IT experts ventured to gaze into a crystal ball.

The automated system extracts structured information such as patient demographics and clinical assessments from EHRs. It also identifies unstructured information from clinical notes, including the patients’ clinical conditions, symptoms, treatments and so forth. The extracted information is then matched with eligibility requirements to determine a subject’s suitability for a specific clinical trial.

The system’s machine learning component also allows it to learn from historical enrollments to improve its future recommendations, according to the researchers.  Much of the analyses are handled by carefully designed AI algorithms, essentially procedures or formulas that computers use to solve problems by performing a set sequence of specified actions.

Previously the system was successfully pilot tested in a retrospective study published in 2015 by the Journal of the American Medical Informatics Association. The current study tested the solution prospectively and in real time in a busy emergency department environment, where clinical research coordinators recruited patients for six different pediatric clinical trials involving different diseases.

Using the technology in a live clinical environment involved significant collaboration between data scientists, application developers, information service technicians and the end users, clinical staff. “Thanks to the institution’s collaborative environment, we successfully incorporated different groups of experts in designing the integration process of this AI solution.” Ni said.

The researchers listed as limitations the small number of clinical trials used in the study, all from a single clinical department. They also pointed to some lingering issues involving the system’s accuracy at interpreting data. These issues will be resolved in future studies through ongoing enhancements to the technologies and also by testing the system in a wider variety of clinical departments, according to the investigators.


Source: Cincinnati Children’s Hospital Medical Center

25.07.2019

Read all latest stories

Related articles

Photo

Better image quality with fewer sensors

Machine learning improves biomedical imaging

Scientists at ETH Zurich and the University of Zurich have used machine learning methods to improve optoacoustic imaging. This relatively young medical imaging technique can be used for applications…

Photo

Machine learning

How intelligent is Artificial Intelligence?

Scientists put AI systems to the test und provide a glimpse into the diverse “intelligence” spectrum observed in current AI models.

Photo

Machine learning tool

AI can predict survival of ovarian cancer patients

Researchers have created a new machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer. The artificial intelligence software, created…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH